Levis MJ - Search Results

1

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

Karp JE, Smith BD, Resar LS, Greer JM, Blackford A, Zhao M, Moton-Nelson D, Alino K, Levis MJ, Gore SD, Joseph B, Carraway H, McDevitt MA, Bagain L, Mackey K, Briel J, Doyle LA, Wright JJ, Rudek MA. Karp JE, et al. Among authors: levis mj. Blood. 2011 Mar 24;117(12):3302-10. doi: 10.1182/blood-2010-09-310862. Epub 2011 Jan 14. Blood. 2011. PMID: 21239698 Free PMC article. Clinical Trial.

2

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

Levis M, Tse KF, Smith BD, Garrett E, Small D. Levis M, et al. Blood. 2001 Aug 1;98(3):885-7. doi: 10.1182/blood.v98.3.885. Blood. 2001. PMID: 11468194 Free article.

3

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, Small D. Levis M, et al. Blood. 2002 Jun 1;99(11):3885-91. doi: 10.1182/blood.v99.11.3885. Blood. 2002. PMID: 12010785 Free article.

4

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.

Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Tse KF, et al. Leukemia. 2002 Oct;16(10):2027-36. doi: 10.1038/sj.leu.2402674. Leukemia. 2002. PMID: 12357354

5

Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay.

Murphy KM, Levis M, Hafez MJ, Geiger T, Cooper LC, Smith BD, Small D, Berg KD. Murphy KM, et al. Among authors: levis m. J Mol Diagn. 2003 May;5(2):96-102. doi: 10.1016/S1525-1578(10)60458-8. J Mol Diagn. 2003. PMID: 12707374 Free PMC article.

6

FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.

Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D. Zheng R, et al. Blood. 2004 Jan 1;103(1):267-74. doi: 10.1182/blood-2003-06-1969. Epub 2003 Sep 11. Blood. 2004. PMID: 12969963 Free article.

7

Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPalpha expression.

Zheng R, Friedman AD, Levis M, Li L, Weir EG, Small D. Zheng R, et al. Blood. 2004 Mar 1;103(5):1883-90. doi: 10.1182/blood-2003-06-1978. Epub 2003 Oct 30. Blood. 2004. PMID: 14592841 Free article.

8

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Smith BD, et al. Blood. 2004 May 15;103(10):3669-76. doi: 10.1182/blood-2003-11-3775. Epub 2004 Jan 15. Blood. 2004. PMID: 14726387 Free article. Clinical Trial.

9

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects.

Levis M, Pham R, Smith BD, Small D. Levis M, et al. Blood. 2004 Aug 15;104(4):1145-50. doi: 10.1182/blood-2004-01-0388. Epub 2004 May 4. Blood. 2004. PMID: 15126317 Free article.

10

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.

Brown P, Meshinchi S, Levis M, Alonzo TA, Gerbing R, Lange B, Arceci R, Small D. Brown P, et al. Blood. 2004 Sep 15;104(6):1841-9. doi: 10.1182/blood-2004-03-1034. Epub 2004 May 27. Blood. 2004. PMID: 15166029 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

228 results

Search Page

Filters